VY7523-102: A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Ascending Intravenous Doses of VY7523 in Participants With Early Alzheimer's Disease
This study is to be conducted in participants with early Alzheimer's Disease to test VY7523, a new drug being researched for treatment of Alzheimer's Disease. This study will look at how safe the drug is and how it works in the brain. It was first tested in normal, healthy participants who volunteered to participate. The study will look at three different dose levels, starting with the lowest dose first and moving to higher doses and more participants after safety has been reviewed by doctors and researchers. Some patients will receive drug while others will receive placebo. This will help to better compare how the drug works between participants receiving drug and placebo. The study will last up to 6 months for the lower dose groups and 12 months for the highest dose group.
• Clinical diagnosis of early AD, defined as:
‣ Meet the NIA-AA core clinical criteria for MCI due to AD or mild AD.
⁃ Mini Mental State Examination (MMSE) score between 18 and 30, inclusive, at Screening (Cohort 1 and 2) and score between 22 and 30, inclusive, at Screening (Cohort 3).
⁃ Report a history of subjective memory decline with gradual onset and slow progression over at least the last 6 months before Screening; must be corroborated by an informant/caregiver.
⁃ CDR Memory Box score ≥0.5 CDR global score of 0.5 for MCI due to AD or 0.5 or 1 for mild AD.
• Evidence of pathology consistent with AD diagnosis:
‣ For Cohort 1 and Cohort 2 only, by documented historical amyloid PET showing imaging agent uptake into the brain conducted within 24 months before screening OR elevated plasma pTau217/np-Tau217 ratio within the Screening Period.
⁃ For Cohort 3 only, evidence of pathology consistent with AD diagnosis by both:
• Evidence of Tau PET imaging agent uptake into the brain by central read AND
∙ Evidence of positive brain amyloid pathology as indicated by one of the following:
• <!-- -->
‣ Documented historical amyloid PET showing imaging agent uptake into the brain conducted within 24 months before screening OR
⁃ CSF beta amyloid and tau levels consistent with AD diagnosis within the Screening Period.
• Body mass index (BMI) ≥18 and ≤35 kg/m2 at Screening.
• Apart from the clinical diagnosis of early AD, participant must be in good health, based on medical history and screening assessments.
• If participant is receiving an approved symptomatic AD treatment such as but not limited to acetylcholinesterase inhibitor (AChEIs), memantine, rivastigmine, galantamine and tacrine for AD, participant must be on a stable dose for at least 8 weeks prior to Screening.
‣ Treatment-naive participants for AD can be entered into the study.
⁃ Unless otherwise stated, participants must have been on stable doses of all other (non-AD-related) permitted concomitant medications for at least 4 weeks prior to Screening.
⁃ Participants currently on β amyloid therapies may not be enrolled.
• Must have an identified reliable informant/caregiver (defined as a person able to support the participant for the duration of the study e.g., spouse, sibling, close friend, who spends at least 10 hours per week with the participant) who assented to:
‣ Accompany the participant to clinic visits.
⁃ Provide information to study Investigator/staff about functioning, cognitive abilities and AEs.
⁃ Support participants returning for per-protocol follow-up visits and procedures.